Park Ha Biological Technology is trading 5.29% higher at $2.39, reversing its September 9 decline to $2.27, with no clear company-specific catalyst identified.
- A new investor-alert release reported a securities class-action lawsuit alleging securities fraud and market-manipulation activity.
- The negative lawsuit news does not clearly explain the gain, while broader markets are lower.